Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Roshan Katekar, Sumati Sen, Mohammed Riyazuddin, Athar Husain, Richa Garg, Saurabh Verma, Kalyan Mitra & Jiaur R. Gayen. (2023) Augmented experimental design for bioavailability enhancement: a robust formulation of abiraterone acetate. Journal of Liposome Research 33:1, pages 65-76.
Read now
Read now
Divakar Selvaraj, Santhoshkumar Muthu, Satvik Kotha, Ramachandra Setty Siddamsetty, Sasikumar Andavar & Saravanan Jayaraman. (2021) Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking, in-vitro and molecular dynamics study. Journal of Biomolecular Structure and Dynamics 39:2, pages 621-634.
Read now
Read now
Athanasios E. Dellis & Athanasios G. Papatsoris. (2019) Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 20:2, pages 163-172.
Read now
Read now
Articles from other publishers (20)
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
161
204
.
Xupeng Wu, Haisong Han, Chao Zhang & Wei Song. (2022) The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Oncology 2022, pages 1-14.
Crossref
Crossref
Aleksandra Sochacka-Ćwikła, Marcin Mączyński & Andrzej Regiec. (2022) FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 27:7, pages 2259.
Crossref
Crossref
Poojari VenkateshUmasankar KulandaiveluGSN Koteswara RaoGuntupalli ChakravarthiRajasekhar Reddy AlavalaBandlamuri Rajesh. (2022) Development and validation of a stability indicating UPLC method for determination of Darolutamide in its tablet formulation. Research Journal of Pharmacy and Technology, pages 165-170.
Crossref
Crossref
Mohammad Hassan Moshafi, Saeid Ghasemshirazi & Ardavan Abiri. (2020) The art of suicidal molecular seduction for targeting drug resistance. Medical Hypotheses 140, pages 109676.
Crossref
Crossref
Eric Lévesque, Adrien Labriet, Hélène Hovington, Éric P. Allain, Luciana Melo-Garcia, Michèle Rouleau, Hervé Brisson, Véronique Turcotte, Patrick Caron, Lyne Villeneuve, Mickaël Leclercq, Arnaud Droit, Etienne Audet-Walsh, David Simonyan, Yves Fradet, Louis Lacombe & Chantal Guillemette. (2020) Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British Journal of Cancer 122:7, pages 1068-1076.
Crossref
Crossref
Namrata Khurana & Suresh C. Sikka. (2019) Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences 20:9, pages 2066.
Crossref
Crossref
Michael Ulm, Arvind V Ramesh, Keely M McNamara, Suriyan Ponnusamy, Hironobu Sasano & Ramesh Narayanan. (2019) Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections 8:2, pages R10-R26.
Crossref
Crossref
Patrick Caron, Véronique Turcotte, Eric Lévesque & Chantal Guillemette. (2019) An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives. Journal of Chromatography B 1104, pages 249-255.
Crossref
Crossref
Neeraj Kumar Saini, Suresh P. Sulochana, Vinay Kiran, Mohd Zainuddin & Ramesh Mullangi. (2018) A novel dried blood spot LC-MS/MS method for the quantification of apalutamide in mouse whole blood: Application to pharmacokinetic study in mice. Biomedical Chromatography 32:11, pages e4344.
Crossref
Crossref
Namrata Khurana & Suresh Sikka. (2018) Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer. Cancers 10:10, pages 352.
Crossref
Crossref
Yang Su, Yue Liu, Christopher R. Behrens, Scott Bidlingmaier, Nam-Kyung Lee, Rahul Aggarwal, Daniel W. Sherbenou, Alma L. Burlingame, Byron C. Hann, Jeffry P. Simko, Gayatri Premasekharan, Pamela L. Paris, Marc A. Shuman, Youngho Seo, Eric J. Small & Bin Liu. (2018) Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight 3:17.
Crossref
Crossref
Gurulingappa Hallur, Buchi Reddy Purra, Suresh P Sulochana, Neeraj Kumar Saini, Prasanthi Daram, Mohd Zainuddin & Ramesh Mullangi. (2018) Validation of an LC-ESI–MS/MS method for the determination of apalutamide, a novel non-steroidal anti-androgen in mice plasma and its application to a pharmacokinetic study in mice. Journal of Pharmaceutical and Biomedical Analysis 153, pages 260-266.
Crossref
Crossref
Namrata Khurana, Hogyoung Kim, Partha K. Chandra, Sudha Talwar, Pankaj Sharma, Asim B. Abdel-Mageed, Suresh C. Sikka & Debasis Mondal. (2017) Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. Oncology Reports 38:5, pages 2774-2786.
Crossref
Crossref
Sreekanth Dittakavi, Pavan Kumar V.S.P. Nagasuri, Suresh P. Sulochana, Syed Mohd Saim, Sadanand R. Mallurwar, Mohd Zainuddin, Purushottam Dewang, Sriram Rajagopal & Ramesh Mullangi. (2017) LC–MS/MS-ESI method for simultaneous quantification of darolutamide and its active metabolite, ORM-15341 in mice plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 145, pages 454-461.
Crossref
Crossref
J.M. Wolff & H.P. Schmid. (2015) Testosteron im Management des metastasierten ProstatakarzinomsTestosterone in the management of metastatic prostate cancer. Der Urologe 54:11, pages 1578-1583.
Crossref
Crossref
Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles, Thomas W. Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia S. Higano, Mary-Ellen Taplin, Thomas W. Griffin, Mary B. Todd, Margaret K. Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan & Fred Saad. (2014) Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Urology 66:5, pages 815-825.
Crossref
Crossref
M. Schulze, H. Stiegler, C. Thielecke, C. Colling & A.S. Merseburger. (2014) Querschnittsanalyse zur Routinebehandlung von ProstatakrebspatientenCross-sectional analysis of routine treatment for prostate cancer patients. Der Urologe 53:6, pages 865-870.
Crossref
Crossref
Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby & Timothy M. Lestingi. (2014) Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study. Clinical Genitourinary Cancer 12:1, pages 27-32.
Crossref
Crossref
Kazushi Watanabe, Akio Kakefuda, Minoru Yasuda, Kentaro Enjo, Aya Kikuchi, Takashi Furutani, Yoichi Naritomi, Yukio Otsuka, Minoru Okada & Mitsuaki Ohta. (2013) Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: A novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. Bioorganic & Medicinal Chemistry 21:17, pages 5261-5270.
Crossref
Crossref